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In response: Cox’s letter (1) con-
tains a number of false assumptions,
errors, misleading assertions, and
misquotations. Cox asserts that annu-
ally 1 person or fewer in the United
States will experience an adverse
effect because of fluoroquinolone use
in poultry. He reduces 10-fold my ref-
erenced risk for persons acquiring
Campylobacter infections from poul-
try (2). His unrealistically low esti-
mate is not given in his referenced
citation. His estimated risk is also
much lower than in the reference 2,
which Cox himself quotes, “Poultry is
the most common cause of sporadic
cases of campylobacteriosis in the
United States” (Economic Research
Service of the US Department of
Agriculture) (3). Cox knows that his
assertion (4) that poultry make little or
no contribution to human
Campylobacter infections has been
extensively examined and found to be
wrong. Indeed, an entire section in a
recent US Food and Drug
Administration (FDA) determination
was written about the unreliability of
Cox’s testimony and these assertions,
a finding made by both the FDA com-
missioner and an administrative law
judge (5,6).
Cox also misquotes Busby et al.
(3) when he asserts that only 0.6% of
persons with Campylobacter infec-
tions benefit from antimicrobial
drugs. The Busby article states that
0.6% of persons with Campylobacter
infections need “hospitalization,” not
how many would benefit from antimi-
crobial drug therapy. Cox has thus
made a misleading attribution (some-
thing he has previously been found to
do [5]). 
Busby et al. (3) estimated that in
1993, ≈1,500,000 persons in the
United States acquired Campylo-
bacter infections from food sources.
Even if the proportion who can bene-
fit from receiving antimicrobial drugs
is as low as 2%, this translates to
30,000 persons. If 20% of these infec-
tions were caused by fluoro-
quinolone-resistant Campylobacter
spp., then 6,000 persons would poten-
tially have their therapy and outcome
compromised, rather than the 1 person
that Cox would have us believe. More
realistic is the figure of 24,000 per-
sons estimated previously to be at risk
of having an adverse outcome (or
≈285 persons for every 1 million
chickens treated with fluoro-
quinolones) (1). Cox’s assumptions
and calculations thus seem flawed and
unrealistic.
Peter Collignon*
*The Canberra Hospital, Woden, Australian
Capital Territory, Australia 
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Biodefense Shield
and Avian Influenza 
To the Editor: In defending
against avian influenza virus H5N1,
the possibility of adopting treatments
being developed for biodefense
should not be overlooked. Biodefense
medicine primarily concerns respira-
tory infections because bioweapons in
their deadliest form disperse Bacillus
anthracis and Yersinia pestis, the
causes of anthrax and plague, and
highly contagious viruses like small-
pox, Ebola, and Marburg as aerosols.
The National Institutes of Health and
Department of Defense have funded
developing novel biodefense medica-
tions designed to stimulate innate
mucosal immunity by using interfer-
ons (IFNs) and interferon inducers.
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We suggest that studies begin imme-
diately to explore the potential of
IFNs to prevent infections and reduce
deaths caused by avian influenza
viruses in animal models and humans.
Modulating innate mucosal immu-
nity is promising as a rapid-acting,
broad-spectrum approach to combat
bioterrorism (1). Innate immunity, the
initial response to a pathogen, is
potentially capable of eradicating
infection. Even when the innate
immune response cannot eliminate a
virus, it may substantially reduce viral
load, reduce pathology, facilitate
clearing of the virus by the adaptive
immune response, and slow the
spread of infection (1). As biodefense
medications, IFNs and IFN-inducers
are under development for
aerosolized delivery to the lungs
(2,3). Conventional IFN administra-
tion by injection often results in low
concentrations at target sites and high
concentrations in circulation, which
may cause serious side effects.
Aerosolized delivery minimizes side
effects and produces more rapid clini-
cal responses. Inhaled IFNs have
proven to be well tolerated and bene-
ficial for rhinovirus infection (4) and
pulmonary tuberculosis (5).
Medications being developed to
prevent infections caused by viral
bioweapons and other diseases
include 1) Oral IFN-α or Alferon low
dose oral (LDO) (Hemispherx
Biopharma, Inc., Philadelphia, PA,
USA); 2) inhalable IFN-γ (InterMune,
Brisbane, CA, USA); 3) dsRNA [Poly
(ICLC)] or Ampligen (Hemispherx
Biopharma, Inc.); 4) ssRNA (Aldara
and Resiquimod from 3M
Pharmaceuticals, St. Paul, MN,
USA); and 5) CpG7909 and
CpG10101 oligonucleotides (Coley
Pharmaceutical Group, Wellesley,
MA, USA) (2). These drugs have
either been approved by the Food and
Drug Administration (FDA) (Aldara),
are in clinical trials (Alferon LDO,
inhalable IFN-γ, Resiquimod,
CPG7909, and CpG10101), or at a
preclinical stage of development
(Ampligen). Aldara is approved for
genital warts, actinic keratoses, and
basal cell carcinoma. Others drugs are
being tested for aerosolized delivery
to modulate mucosal immunity of the
respiratory tract. All could be expedi-
tiously tested with inhalational or
intranasal administration in H5N1
models with mice, ferrets, pigs, and
monkeys. 
IFN-α and IFN-γ work by binding
their receptors and activating down-
stream antiviral pathways involving
the dsRNA-dependent protein kinase
(PKR), the 2′, 5′ oligoadenylate syn-
thetase/RNase L, or the MxA protein.
dsRNA, ssRNA, and CpG oligonu-
cleotides are ligands for toll-like
receptors (TLRs) and modulate
antiviral immunity through TLR sig-
naling pathways and IFN induction
(2). At the cellular level inside the
lungs, these drugs will enhance
phagocytotic and cytolytic activity in
alveolar macrophages.
Once infection is established,
H5N1 resists the antiviral effects of
IFNs and tumor necrosis factor-α (6).
Resistance is associated with the non-
structural gene of H5N1 and may be 1
mechanism for H5N1’s extraordinary
virulence. Therefore, prophylactic use
of IFNs and IFN-inducers is critical to
combat H5N1. They may also be
effective if administered immediately
after infection. 
IFN resistance also exists for other
viral infections. For instance,
poxviruses including vaccinia virus
encode 2 proteins that interfere with
RNaseL and PKR pathways and 2 sol-
uble IFN receptors that interfere with
IFN-induced antiviral pathways.
Nevertheless, at least in animal mod-
els, pre-infection administration of
exogenous IFN can reduce deaths and
poxvirus viral load. In mice,
intranasal administration of IFN-α
and IFN-γ prevents lethal vaccinia
infection (3). IFN-α, IFN-γ, and an
IFN inducer, Poly (ICLC), protect
mice infected with H1N1 influenza
virus (7). Hence, we suggest that anti-
H5N1 prophylaxis by IFN-stimulated
innate mucosal immunity is a promis-
ing therapy worth immediate investi-
gation in animal models.
A second mechanism proposed to
explain H5N1 virulence is also IFN
related. This is the “cytokine storm,”
as shown by elevated levels of proin-
flammatory cytokines including IFNs
found in 2 patients who died of H5N1
infections (8). Cytokine storms can
result in autoimmune reactions, tissue
damage, or septic shock. High IFN
doses for long periods may exacerbate
autoimmunity. However, despite sim-
ilar cytokine storms (9), some severe
acute respiratory syndrome patients
respond well to IFN therapy (10).
Optimal formulation and regimen of
IFN administration could be crucial to
effective anti-H5N1 prophylaxis. In
the interests of safety, we propose that
initial prophylaxis studies use rela-
tively low IFN doses for short periods
(≈1–2 weeks).
It is unlikely that all of these drugs
will effectively protect against H5N1.
And a drug that is effective might not
work for everyone; genetic polymor-
phism influences IFN response.
However, FDA approval of even one
of them might save many lives. 
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